Cycloserine

Drug Profile

Cycloserine

Alternative Names: Cycloserine-D; D-Cycloserine; SC 49088

Latest Information Update: 29 Apr 2003

Price : $50

At a glance

  • Originator Pfizer
  • Class Antituberculars; Isoxazoles; Small molecules
  • Mechanism of Action Glycine NMDA-associated agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 08 Apr 2002 A study has been added to the Psychotic Disorders therapeutic trials section
  • 18 Aug 1999 A study has been added to the Psychotic disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top